Combined criteria for dose optimisation in early phase clinical trials by Alam, MI et al.
Received ; Revised ; Accepted
DOI: xxx/xxxx
RESEARCH ARTICLE
Combined criteria for dose optimisation in early phase clinical
trials
M. Iftakhar Alam1 | D. Stephen Coad2 | Barbara Bogacka2
1Institute of Statistical Research and
Training, University of Dhaka, Dhaka
1000, Bangladesh
2School of Mathematical Sciences, Queen
Mary University of London, London E1
4NS, U.K.
Correspondence
M. Iftakhar Alam, Institute of Statistical
Research and Training, University of Dhaka,
Dhaka 1000, Bangladesh.
Email: iftakhar@isrt.ac.bd
The paper aims to investigate whether any bridge is possible between so-called best
intention and 퐷-optimum designs. It introduces combined criteria for dose optimi-
sation in seamless phase I/II adaptive clinical trials. Each of the optimality criteria
considers efficacy and toxicity as endpoints and is based on the probability of a
successful outcome and on the determinant of the Fisher information matrix for esti-
mation of the dose-response parameters. In addition, one of the criteria incorporates
penalties for choosing a toxic or inefficacious dose. Starting with the lowest dose,
the adaptive design selects the dose for each subsequent cohort that maximises the
respective defined criterion. The methodology is illustrated with a dose-response
model that assumes trinomial responses. Simulation studies show that the method is
capable of identifying the optimal dose accurately without exposing many patients
to toxic doses.
KEYWORDS:
adaptive design, continuation ratio model, 퐷-optimum design, penalty function, phase I/II trial
1 INTRODUCTION
A phase I clinical trial is the first step in applying a new drug to humans. The designs for phase I trials, particularly those in
cancer, focus on the maximum tolerated dose (MTD).1 This MTD is based on toxicity and it ignores efficacy. Phase II designs
aim to determine the efficacy level of an experimental drug, assuming that a dose range has been established in phase I. For
cytotoxic agents that are used in treating cancer, it is believed that the higher doses are more likely to be toxic, and also more
likely to kill the cancer cells and therefore be efficacious. As a consequence, such designs for cancer clinical trials assume
that the dose-toxicity and dose-efficacy relationships are both monotone non-decreasing functions of dose. Therefore, the MTD
determined from the phase I trial will provide a dose with a desirable level of efficacy.
In recent years, targeted therapies have drawn attention for treating cancer patients. These are drugs or other substances that
block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression and
spread of cancer. Wages and Tait2 discussed the emergence of targeted agents in oncology drug development. For these targeted
agents, the dose-efficacy curve may not increase with dose. Therefore, conducting the phase II trials based on the MTD from
phase I for those agents may not be an efficient way of running the trial. In such situations, it will be useful to consider toxicity
and efficacy simultaneously to determine an optimum dose for further investigation in the next phase.
Also, for drugs other than those for cancer, a dose will be acceptable only if it is efficacious and safe. Since it is quite difficult
to find a dose which is both efficacious and non-toxic, efforts are necessary to achieve a trade-off between the two. The specific
goal is to find a dose which has a high probability of efficacy and a low probability of toxicity. Regardless of the method, phase I
trials are small in size and consequently the dose-toxicity curves may not be well estimated. They often determine a dose which
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can be found to be either unacceptably toxic or ineffective in a later phase. Seamless phase I/II trials are larger in comparison,
and so the associated methods could potentially lead to more efficient dose selection.
Different methods are being developed to increase the popularity of seamless phase I/II clinical trials. There are designs
proposed by Thall and Russell,3 Thall and Cook,4 and Zhang et al.5 These designs have the intention of allocating the best dose
to the cohort of patients based on the current knowledge and are known as the “best intention designs". They may lead to poor
learning of the dose-response relationship. In contrast, there are methods which rely on optimal design criteria for estimation of
model parameters. Heise and Myers6 constructed the 퐷-optimal design using the Gumbel model for bivariate binary data. Fan
and Chaloner7 described the퐷-optimal design for trinomial responses using a continuation ratio model. Dragalin and Fedorov8
considered binary outcomes for each endpoint and used either Gumbel bivariate binary logistic regression or the Cox bivariate
binary model. They proposed a penalised 퐷-optimal design to improve dose allocation to the cohorts. The design maximises
the information under the control of a penalty function for treating patients at doses which are too low or too high. Dragalin et
al9 proposed a design for the combination of two drugs when both efficacy and toxicity are endpoints. This can be viewed as an
extension of their previous work, as it utilises the multivariate probit model and generalises the results to combinations of two
drugs. Pronzato10 developed a penalised 퐷-optimum design that is flexible in setting a compromise between the information
gained and the cost of the experiment. All of these designs focus on the efficient estimation of the dose-response parameters,
so that the optimum dose can be obtained more accurately at the end of the trial. However, they may often expose patients to
subtherapeutic or toxic doses on their way to efficient parameter estimation. Alam et al11 developed a design that, in addition to
efficacy and toxicity endpoints, also considered pharmacokinetic information in dose escalation.
Pocock12 pointed out that a trial should involve a balance between individual and collective ethics and achieving such a balance
is not that simple. Individual ethics are concerned with the quality of treatment that each successive cohort in a trial receives.
On the other hand, collective ethics are concerned about the future benefits of the patients from the collected information in
the trials. This paper investigates whether any trade-off between the best intention designs taking care of individual ethics and
퐷-optimal designs focusing more on collective ethics is possible. The underlying idea is to develop a design that exposes few
cohorts in a trial to either subtherapeutic or toxic doses and that can also find the optimum dose accurately. In other words, the
paper aims to achieve a balance between individual and collective ethics.
The paper is organised as follows. Section 2 introduces the proposed dose-optimisation criteria. The stopping rules are
described in Section 3. Some measures to evaluate the designs are given in Section 4. To illustrate the methodology, an example
is introduced in Section 5. Finally, a discussion appears in Section 6.
2 METHODS
In this section, we present optimisation criteria to find the best dose in a seamless phase I/II adaptive clinical trial. The method
is general and can be applied to any dose-response model that allows for efficacy and toxicity endpoints.
2.1 General idea
We assume that a set of candidate doses  = {푥(1),… , 푥(푑)}, developed from preclinical studies or from very early phase Ia
clinical studies, is known. We develop a model-based adaptive procedure to investigate the doses for recommendation in later
phases of clinical trials. At each stage of a trial, the optimum dose is selected based on one of the newly-defined optimisation
criteria. We use a linear combination of the probability of success and 퐷-optimality, both with and without a penalty function
applied, to achieve the best of the two approaches. The procedure initially assigns the lowest dose to a cohort of patients. The
successive cohorts then receive doses based on the chosen criterion until the trial stops according to the stopping rules. The
following sections give details of the proposed method.
2.2 Maximisation of probability of success
Since our design is for seamless phase I/II trials, there are two endpoints, efficacy and toxicity. Consideration of binary outcomes
for each of the endpoints will lead to four possible responses. The corresponding probabilities of the outcomes can be represented
as 휓00, 휓01, 휓10 and 휓11, where the double subscript indicates presence and absence of efficacy and toxicity in the response.
Trinomial responses are also common in such dose-finding studies, where an outcome which is neither efficacious nor toxic is
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treated as a neutral response. The outcome which is efficacious but non-toxic is regarded as a success. If an outcome is toxic,
irrespective of the efficacy, it is considered as a toxic outcome. The probabilities of these outcomes are represented as 휓0, 휓1 and
휓2, respectively. For the bivariate binary case, 휓10 is regarded as the probability of a success. To keep the following discussion
general, we denote the probability of a success outcome by 휓푆 . In the trinomial case, 휓1 is taken to be 휓푆 . This is a function of
dose and it usually depends on some unknown model parameters 흑.
In what follows, Bayesian parameter estimation is used. Assume that we are at the 푘th stage of the adaptive procedure, and,
based on the current data, we have the posterior estimates 흑̂푘 of the dose-response model parameters. Then we select the dose
푥휓푆푘+1 for the next cohort of patients that maximises the probability of success, that is,
푥휓푆푘+1 = argmax푥∈ 휓푆(푥, 흑̂푘). (1)
The above criterion is defined so that it allocates the doses with the highest probability of efficacy assessed from the current
knowledge at stage 푘. The issue of allocating the most efficacious doses during a trial is very important from an ethical point of
view. Note that 휓푆 is often called a utility function in optimisation theory.
The criterion, by definition, does not take into account the efficiency of parameter estimation. Rather it allows the current best
dose to be allocated with the hope that some valuable information can be collected. The designs that allocate the best dose have
become very popular in dose-finding studies. Some notable results in this direction are by Zhang et al,5 Thall and Russell,3 and
Thall and Cook.4 But these designs have the limitation that they may not converge to the right dose, as indicated in Pronzato13
and Fedorov et al.14
2.3 Maximisation of determinant of Fisher information matrix
This approach allocates those doses to the cohorts which contribute most to the efficient estimation of the dose-response
parameters. Assume that we are at the 푘th stage in an adaptive clinical trial and that the doses allocated to the cohorts so far
are 흃푘 = {푥1, 푥2,… , 푥푘}. Also, based on the data collected from the 푘 cohorts, we have the posterior estimates 흑̂푘 of the
dose-response parameters. Let us define the augmented Fisher information matrix (FIM) as
푴(푥|흃푘, 흑̂푘) = 푘푘 + 1푴(흃푘, 흑̂푘) + 1푘 + 1푰(푥, 흑̂푘), (2)
where푴(흃푘, 흑̂푘) = ∑푘푖=1 푰(푥푖, 흑̂푘) and 푰(푥, 흑̂푘) is the estimated Fisher information matrix for a cohort which received dose 푥.For our dose-response model, the expression for 푰(푥,흑) is given in (11). In all of the designs that we consider in this paper,
the cohort size is assumed to be the same. Atkinson et al15 discussed the construction of designs based on augmented FIMs.
Bogacka et al16 used the same approach for the construction of adaptive designs.
We select the dose 푥퐷푘+1 for the next cohort of patients which maximises the criterion Φ퐷, that is,
푥퐷푘+1 = argmax푥∈ Φ퐷{푴(푥|흃푘, 흑̂푘)}, (3)
where ΦD{푴} = |푴|. This is well known in the statistical literature as the 퐷-optimality criterion for precise estimation of the
parameters: see, for example, Atkinson et al17 and Fedorov and Hackl.18 The Cramér-Rao inequality tells us that the covariance
matrix of the parameter estimators is at least, and asymptotically approaches, the inverse of the FIM. Therefore, by maximising
the determinant of the FIM, we minimise the asymptotic lower bound for the generalised variance of the estimated model
parameters. Since a dose-response model is usually non-linear, the FIM depends on the model parameters. As indicated earlier,
we utilise the current estimates of the parameters to optimise the criterion and consequently the design is locally 퐷-optimal.17
Because the doses allocated to the cohorts in this design are often found at the extremes of the design region  , such a design
has the limitation that patients in a trial may be exposed to non-efficacious or highly toxic doses.
2.4 Maximisation of determinant of penalised FIM
To reduce the possibility of exposing patients to extreme doses, we can introduce a penalty function in the search for퐷-optimum
doses and consider a penalised 퐷-optimum design, as in Dragalin and Fedorov.8 This design tries to improve the individual
ethics of a trial.
We denote the penalty function for an observation taken at the design point 푥 by 휑(푥,흑). Following Dragalin and Fedorov,8
we choose
휑(푥,흑) = {휓푆(푥,흑)}−퐶푆{1 − 휓푇 (푥,흑)}−퐶푇 , (4)
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where휓푆 and휓푇 are the probabilities of success and toxicity at a given dose, respectively, and퐶푆 and퐶푇 are control parameters
used to construct an appropriate penalty function at the low and high dose levels. The function is defined so that the lower the
probability of success and/or the higher the probability of toxicity at the assigned dose, the higher the penalty for the observation
taken. Note that, in the bivariate binary model case, 휓01 + 휓11 is considered as 휓푇 , while in the trinomial model it is 휓2.
For a given dose 푥 and values of the parameter vector 흑, the larger the values of 퐶푆 and 퐶푇 are, the higher the value of the
penalty function will be, and thus the design will avoid allocating doses with a low probability of efficacy or a high probability of
toxicity to the patients. The case 휑(푥,흑) = constant means the same penalty across the doses and consequently will lead to the
original 퐷-optimum design. The larger the values of the control parameters are, the further the design is from the 퐷-optimum
design and the less efficient is the parameter estimation.
The penalised 퐷-criterion takes into account the penalty function in (4). In this version of the 퐷-optimum design, we select
the dose at the 푘th stage as
푥푃퐷푘+1 = argmax푥∈ ΦPD{푴(푥|흃푘, 흑̂푘)}, (5)
where ΦPD{푴} = |푴∕흋|. The matrix푴(푥|흃푘, 흑̂푘) is defined in (2) and
흋(푥|흃푘, 흑̂푘) = 푘푘 + 1흋(흃푘, 흑̂푘) + 1푘 + 1휑(푥, 흑̂푘),
where 흋(흃푘, 흑̂푘) = ∑푘푖=1 휑(푥푖, 흑̂푘). According to Dragalin and Fedorov,8 the penalised adaptive 퐷-optimum design is moreefficient than the adaptive 퐷-optimum design in that both the precision of estimation and the information per cost are higher in
the former case. The authors also found that the convergence property holds for the penalised 퐷-optimum design.
The measures based on the information for the evaluation of a design are now described. In the theory of optimal design, the
normalised FIM is defined as(흃푁 ,흑) =푴(흃푁 ,흑)∕푁 , where푴(흃푁 ,흑) = ∑푁푖=1 푰(푥푖,흑) and푁 is the number of cohorts in atrial. Now, |(흃푁 ,흑)| gives the information per observation in the trial. The higher the value of the information per observation,
the higher the estimation precision is. Similarly, the information per cost can be obtained as |푴(흃푁 ,흑)|1∕푝∕흋(흃푁 ,흑), where
흋(흃푁 ,흑) =
∑푁
푖=1 휑(푥푖,흑) and 푝 is the number of model parameters.8 A design with a higher information per cost is regardedas more efficient.
2.5 Combined criteria
Although the penalised 퐷-criterion introduces a penalty function to improve the quality of treatment during dose escalation,
we have found it not to be improved as expected. Therefore, further effort has been taken with the combined criteria defined
below. Also, clinicians may be interested in achieving several objectives, such as efficient estimation of the model parameters
and allocation of the most efficacious doses to the cohorts during a clinical trial. The combined criteria in (6) and (7) balance
these two objectives. Each of the criteria is defined so that one can obtain the design which ensures either efficient parameter
estimation or efficacious dose allocation or a combination of both. The two criteria are named as the penalised combined criterion
and the simple combined criterion, respectively.
The penalised combined criterion is a linear combination of the determinant of the Fisher information matrix for the dose-
response model, penalised for inefficacy and toxicity, and the probability of success. On the other hand, the simple combined
criterion does not penalise for inefficacy and toxicity. At each stage of the adaptive trial, we select that dose for which the
criterion is maximised.
To implement the penalised criterion, we initially determine the doses 푥휓푆푘+1 and 푥푃퐷푘+1 in (1) and (5) that maximise the prob-ability of success and the determinant of the penalised FIM, respectively. Since the determinant and the probability of success
may have quite different magnitudes, we scale them at the dose 푥 as
퐸푃퐷(푥) =
Φ푃퐷{푴(푥|흃푘, 흑̂푘)}
Φ푃퐷{푴(푥푃퐷푘+1|흃푘, 흑̂푘)}
and
퐸휓푆 (푥) =
휓푆(푥, 흑̂푘)
휓푆(푥
휓푆
푘+1, 흑̂푘)
.
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The penalised combined criterion then selects the dose 푥푘+1 for the next cohort of patients so that
푥푘+1 = argmax푥∈
{
푎퐸푃퐷(푥) + (1 − 푎)퐸휓푆 (푥)
}
, (6)
where 푎 is some weight such that 0 ≤ 푎 ≤ 1.
If the 퐷-optimum dose 푥퐷푘+1 and 퐸퐷(푥) are chosen instead, then the simple combined criterion takes the form
푥푘+1 = argmax푥∈
{
푎퐸퐷(푥) + (1 − 푎)퐸휓푆 (푥)
}
. (7)
This is a special case of the penalised combined criterion if 휑(푥,흑) = constant. This is due to the fact that, when 휑(푥,흑) =
constant, the penalised 퐷-criterion reduces to the 퐷-criterion. Pronzato10 considered a similar compound criterion to balance
between gaining information and the cost of the experiment (cf. Remark 9.2).19 Compound criteria were introduced by Läuter.20
Obviously, the results will depend on the choice of 푎. It is clear that, when 푎 = 1, the combined criterion is simply the
penalised 퐷-criterion or 퐷-criterion. Similarly, for 푎 = 0, we have dose selection based on the probability of success only. For
any other choice of 푎, the design is expected to allocate the most efficacious doses to the cohorts and to give precise estimates
of the parameters leading to the recommendation of the best dose for further study. As we show later, the choice of 푎 is an
important component of the method.
Although the probability of success appears twice in the penalised combined criterion, through 퐸푃퐷(푥) and 퐸휓푆 (푥), its rôleis different in each case. In the penalised 퐷-criterion, the probability of success is used to scale the FIM so that doses with low
efficacy or high toxicity result in small values for the determinant of the FIM. The 퐸푃퐷 part of the criterion guides us to choose
the dose that will provide maximum information regarding parameter estimation, taking into account the efficacy levels of all of
the available doses. The maximisation of the probability of success on the other hand tends to choose a dose from the efficacy
viewpoint, without accounting for parameter estimation. A combination of them, as presented above, is expected to facilitate a
balance between the two approaches.
3 STOPPING RULES AND OPTIMUM DOSE
We check the possibility of stopping early for futility and/or toxicity at each stage of a trial. More specifically, at the 푘th stage,
we check whether
max
푥∈ {휓푆(푥, 흑̂푘) − 휓푇 (푥, 흑̂푘)} < 휆.
If it is found to be true, we also check whether 휓푇 (푥, 흑̂푘) > 훾 at the dose where the above maximum difference occurs. If both
the conditions are found to be satisfied, we stop the trial for futility and/or toxicity and recommend no dose as the optimum
dose (OD). Otherwise, we continue the trial. The idea behind such stopping is that, if the maximum difference between the
estimated success and toxicity rates is smaller than a desired value 휆 and also the estimated toxicity at that dose is greater than
the acceptable value, then there is no hope of obtaining an OD by continuing this trial. If 휓푆(푥, 흑̂푘) and 휓푇 (푥, 흑̂푘) takes the same
value, then their difference is 0. If 휓푆(푥, 흑̂푘) takes the value 1, then 휓푇 (푥, 흑̂푘) will have value 0, and, in that case, the difference
will be 1. As a consequence, we assume that 0 ≤ 휆 ≤ 1. A small value of 휆 means a flexible checking condition, in the sense
that it will allow less frequent checking of 휓푇 (푥, 흑̂푘) than that at a large value of 휆. We can set 휆 as the difference between 훿 and
훾 . Note that, starting at the first stage, we keep checking for futility and/or toxicity until the penultimate stage of a trial.
Apart from stopping for futility and/or toxicity, a trial is stopped when the same dose is repeated for 푟 cohorts or when the trial
reaches the maximum number of available cohorts 푚, whichever comes first. Terminating early when the same dose is being
repeated saves resources while no more information is obtained.
The optimum dose is defined as the dose that has been repeated 푟 times for the early-stopped trials. For the trials that utilise
the maximum number of cohorts 푚, the optimum dose is defined as the one for which the estimated probability of success is
maximum, subject to the constraints that the estimated probability of toxicity at that dose is no more than an acceptable level
for toxicity 훾 and that the estimated probability of success is at least 훿.
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4 EVALUATION OF THE DESIGNS
To assess the quality of the proposed adaptive design, we introduce two measures of performance: the decision efficiency and
the sampling efficiency. Both are based on the simulation results, where the responses are obtained for some assumed true values
of the model parameters denoted by 흑true. Along with these, we also compute some other measures as presented below.
DECISION EFFICIENCY
The decision efficiency (DE) is based on the distribution 휉̃ of the OD obtained in a simulation study and written as
휉̃ =
{
푥(1) ,… , 푥(푑)
푤̃(1) ,… , 푤̃(푑)
}
,
where 푤̃(푗) denotes the proportion of times that dose 푥(푗) was recommended for the next phase. In other words,
푤̃(푗) =
푞푗
푈
, (8)
where 푞푗 is the number of times that dose 푥(푗) was recommended as optimum in 푈 simulated trials.
To assess how good the recommended dose is, we introduce the ratio 휌 of the probability of success at dose 푥 to the probability
of success at the true optimum dose 푥OD, both calculated at the value 흑true, that is,
휌(푥,흑true) =
휓푆(푥,흑true)
휓푆(푥OD,흑true)
. (9)
Dose 푥OD maximises 휓푆 for 흑true, and hence 휌(푥,흑true) ≤ 1. To measure the global efficiency of the decision regarding the dose
recommended for further study, we calculate the weighted sum
DE =
푑∑
푗=1
푤̃(푗) 휌(푥(푗),흑true) 퐼{푥(푗) ∈ },
where the 푤̃(푗) are defined in (8), 퐼(퐵) is the indicator function of the event 퐵 and is the set of doses for which the probability
of toxicity is below or equal to the acceptable level. If 푥OD ∈  and it is recommended in each of the simulated trials, then the
weight 푤̃(푗) corresponding to 푥OD is 1 and 0 for all other dose levels, and hence DE = 1. Similarly, if all of the recommended
doses are from the toxic region, then the indicator function takes the value 0 for each of them, and hence DE = 0. In general,
0 ≤ DE ≤ 1. If 푥OD does not exist for a dose-response scenario, then we cannot compute 휌(푥,흑true) in (9). However, we can treat
휌 as 1 if no dose is recommended in a trial under such a scenario. If a dose from  is recommended as the OD, then we can treat
휌 as 0. These considerations facilitate the calculation of the DE for that scenario. Similarly, a trial may recommend no dose as
the OD when there exists a true OD in the scenario. The proportion of such recommendations obtained in the simulations can
be ignored in the calculation of the DE.
SAMPLING EFFICIENCY
We define the sampling efficiency (SE) based on the information on the allocated doses to the cohorts over the simulations. The
distribution 휉 of the allocated doses to the cohorts over all simulations is denoted as
휉 =
{
푥(1) ,… , 푥(푑)
푤(1) ,… , 푤(푑)
}
,
where 푤(푗) is the proportion of times that dose 푥(푗) was allocated to the cohorts over all simulated trials. In other words,
푤(푗) = 1
푛total
푈∑
푖=1
푛푗푖, (10)
where 푛total = ∑푈푖=1 푛(푖) and 푛(푖) denotes the number of cohorts used in the 푖th simulated trial. Thus, 푛total is the total number ofcohorts used in all simulations and 푛푗푖 is the number of cohorts given dose 푥(푗) in the 푖th simulation.
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With the 푤(푗) as in (10), we define the SE as
SE =
푑∑
푗=1
푤(푗) 휌(푥(푗),흑true) 퐼{푥(푗) ∈ }.
This criterion assesses the quality of treatment received by the patients during the trials. If the cohorts in the trials only receive
푥OD, then SE = 1. In that case, there will be no experimental variation in the dose level. In general, we can expect the SE to be
appreciably smaller than the DE, unless the variation in 휓푆 over  is small. Here also, 0 ≤ SE ≤ 1.
Hardwick et al21 consider similar efficiency measures. However, they do not penalise for doses which have a probability of
toxicity above the acceptable level. There may be some dose-response scenarios where the maximum value of 휓푆(푥,흑true) is
obtained at a dose for which the probability of toxicity is above the acceptable level. As a result, 휌(푥,흑true)may be greater than 1.
Consequently, a design choosing these doses more frequently will have larger values for their efficiency measures than one that
limits such toxic doses. This should not be the case, since these are the doses which a good design should not choose because
of their toxicity. Therefore, we have presented measures that penalise for toxic doses. The proposed measures are capable of
judging a design selecting low efficacious or high toxic doses as a poor one.
RISKS
A drug development process includes the following: targeted population, sampled patients, a specific patient, a sponsor and
various regulatory agencies. Since in our design we allocate doses to cohorts of patients, by patients here we would mean
cohorts. For the targeted population, the potential loss can be determined by the uncertainty of the recommended optimum dose
푥∗. Like Lai and Robbins,22 we consider the quadratic penalty 휙(푥) = (푥 − 푥∗)2 to assess the risks for various groups. For the
targeted population, the potential loss that is due to the uncertainty in the recommended optimal dose 푥∗ is 퐸{(푥∗푁 − 푥∗)2},where 푥∗푁 is the optimal dose recommended in a trial using 푁 cohorts. Note that the value of 푁 would be between 1 and
푚, as we stop a trial early either for futility and/or toxicity or for repetition of a dose 푟 times. Also, the risk for the targeted
population is the same as the mean square error of the estimate of the optimal dose. For the sampled patients, we can calculate
the risk as 퐸
{∑푁
푖=1(푥푖 − 푥
∗)2
}
, where 푥푖 is the dose allocated to the 푖th patient in a trial. For the 푛th in-trial patient, the risk is
퐸{(푥푛 − 푥∗)2}.
NONPARAMETRIC BENCHMARK
We now describe the construction of the nonparametric benchmark design proposed by Cheung.23 The purpose is to compare
our design with the benchmark produced by that design. In actual trials, the outcome for a patient is observed at the administered
dose only. However, the essence of the nonparametric design is to find responses for a patient at all 푑 dose levels.
Let 푌 = 푌 (푔) denote the patient’s multinomial outcome at dose level 푔 for 푔 = 1,… , 푑 and let 휋(푔) be the associated
probability distribution. Assume that 푌 can take 퐿 + 1 possible values 휔0 < 휔1… < 휔퐿. If we consider trinomial responses,
then 퐿 = 2, and the possible values are 휔0, 휔1 and 휔2. The method defines 휋푙(푔) = 푃 {푌 (푔) ≥ 휔푙} for 푙 = 1,… , 퐿, so that we
obtain the outcome distribution as 휋(푔) = {휋1(푔),… , 휋퐿(푔)}. If we consider trinomial responses, then 휔푙 = 푙 for 푙 = 0, 1, 2.
Now, 휋1(푔) = 푃 {푌 (푔) ≥ 휔1} = 푃 {푌 (푔) ≥ 1} = 푃 {푌 (푔) = 1} + 푃 {푌 (푔) = 2} = 휓1(푔) + 휓2(푔). Similarly, it can be shown
that 휋2(푔) = 휓2(푔) and 휋0(푔) = 1. Note that 휋1(푔) − 휋2(푔) = 휓1(푔).
Now we can draw an outcome 푌 from the distribution 휋 via latent variables. More specifically, for each patient 푖, we randomly
draw a tolerance profile 푈푖1 and 푈푖2 from 푈 (0, 1). For a given dose level 푔, we generate 푌푖(푔) = 휔푙 if 푈푖,푙+1 > 휋푙+1(푔)∕휋푙(푔) and
푈푖푗 ≤ 휋푗(푔)∕휋푗−1(푔) for all 푗 = 1,… , 푙. The generated 푌푖(푔) is a simulated outcome for patient 푖 at dose level 푔. A complete
outcome profile for patient 푖 is {푌푖(1),… , 푌푖(푑)}. Thus, we can obtain the complete outcome profiles for all of the 푚푐 patients
in a trial, where 푐 is the cohort size. Then, at each 푔, we obtain the estimate of 휋 as
휋̂푙(푔) =
1
푚푐
푚푐∑
푖=1
퐼{푌푖(푔) ≥ 휔푙}
for 푙 = 1, 2. Then we determine the optimum dose level 푔∗ such that
푏(휋̂) = 푔∗ = argmax
푔
휓̂1(푔),
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subject to the conditions that 휓̂2(푔∗) ≤ 훾 and 휓̂1(푔∗) ≥ 훿. Note that 휓1 and 휓2 correspond to 휓푆 and 휓푇 , respectively. The dose
corresponding to the level 푔∗ is the OD. Thus, we obtain the distribution of the OD from the simulations for a dose-response
scenario and compare with it the results for our proposed design.
5 AN EXAMPLE
To explore the proposed methodology, we introduce an example which is based on the continuation ratio dose-response model.
As indicated in Section 2.5, a combined criterion is intended to serve two purposes: allocation of the most efficacious doses to
the cohorts and improvement in the estimation of the dose-response parameters. The latter should help to identify the OD more
accurately. Simulation studies, detailed in Section 5.2, are conducted to investigate the properties of the design.
5.1 Dose-response model
Assume that, for each patient, the outcomes can be categorised as neutral, successful or toxic. As mentioned in Section 2.2,
success is referred to as an outcome which is efficacious but non-toxic. The occurrence of these outcomes depends on dose.
We assume an experimental drug for which the probability of a neutral response decreases monotonically with dose and the
probability of toxicity increases monotonically with dose. However, the probability of success may be non-monotonic, increasing
or decreasing. As indicated earlier, the corresponding probabilities are represented by 휓0(푥,흑), 휓2(푥,흑) and 휓1(푥,흑), so that
휓0(푥,흑) + 휓1(푥,흑) + 휓2(푥,흑) = 1, where 흑 is the vector of parameters.
The proportional odds model may be chosen in such a situation, but it requires the dose to have the same effect across the
cumulative logits. As it is difficult to satisfy this assumption, we use a more flexible continuation ratio model,24 which is given
by
log
{
휓1(푥,흑)
휓0(푥,흑)
}
= 휗1 + 휗2푥 and log
{
휓2(푥,흑)
1 − 휓2(푥,흑)
}
= 휗3 + 휗4푥.
The parameter 휗1 represents the baseline log-relative probability, 휗2 reflects the contribution of dose in the log-relative prob-
ability of having a success relative to a neutral outcome, 휗3 is the baseline log-odds and 휗4 is the contribution of dose in the
log-odds of a toxic outcome relative to a neutral or successful one. The above equations have the solutions
휓0(푥,흑) =
1
(1 + 푒휗1+휗2푥)(1 + 푒휗3+휗4푥)
,
휓1(푥,흑) =
푒휗1+휗2푥
(1 + 푒휗1+휗2푥)(1 + 푒휗3+휗4푥)
and
휓2(푥,흑) =
푒휗3+휗4푥
1 + 푒휗3+휗4푥
.
The parameter spaceΘ is restricted so that the above non-linear functions of dose exhibit the assumed behaviour of the responses:
Θ =
{
흑 = (휗1, 휗2, 휗3, 휗4)푇 ∶ 휗1 ≥ 휗3, 휗3 < 0 and 휗2, 휗4 > 0} .
If we are at the 푘th stage in a trial, then 푘 cohorts have been treated with doses selected from the set of ordered doses  . Let 풙
be the 푘× 1 vector of doses with components 푥푙 and let푹 be the 푘× 3 outcome matrix with푹푙 = (푅푙0, 푅푙1, 푅푙2) as the 푙th row,
푙 = 1, 2,… , 푘. Note that 푅푙0 +푅푙1 +푅푙2 = 푐, where 푐 is the number of subjects in a cohort treated with dose 푥푙. The successive
components of 푹푙 are the counts of neutral, successful and toxic responses for the 푙th cohort. Thus, the likelihood function is
퐿푘(흑 ∣ 풙,푹) ∝
푘∏
푙=1
{휓0(푥푙,흑)}푅푙0{휓1(푥푙,흑)}푅푙1{휓2(푥푙,흑)}푅푙2 .
Since maximum likelihood estimation is unsuitable because of small sample sizes at the early stages of a trial, we employ a
Bayesian approach to estimate the parameters 흑. The posterior estimate of 흑 at the 푘th stage is
흑̂푘 =
∫Θ 흑 푝(흑)퐿푘(흑 ∣ 풙,푹)푑흑∫Θ 푝(흑) 퐿푘(흑 ∣ 풙,푹) 푑흑 ,
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where 푝(흑) is the joint prior distribution of the parameters. Let us assume that 0 < 휗2 < 푢1, 0 < 휗4 < 푢2, 푣1 < 휗1 < 푣2 and
푣3 < 휗3 < 푣4, and that the joint prior distribution is uniform. Then we obtain
푝(흑) = 2
푢1푢2(푣2 − 푣3)2
, 흑 ∈ Θ̃,
where
Θ̃ =
{
흑 ∶ 푣3 < 휗3 ≤ 휗1 < 푣2, 0 < 휗2 < 푢1, 0 < 휗4 < 푢2} .
The associated FIM for the model parameters is of the form
푰(푥,흑) = 푐
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎣
휓1(1 − 휓2)
휓0(1 + 푒휗1+휗2푥)2
푥휓1(1 − 휓2)
휓0(1 + 푒휗1+휗2푥)2
0 0
푥휓1(1 − 휓2)
휓0(1 + 푒휗1+휗2푥)2
푥2휓1(1 − 휓2)
휓0(1 + 푒휗1+휗2푥)2
0 0
0 0 휓2(1 − 휓2) 푥휓2(1 − 휓2)
0 0 푥휓2(1 − 휓2) 푥2휓2(1 − 휓2)
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎦
. (11)
This can be easily obtained from (7) and (22) in Atkinson et al.15 Matrix 푰(푥,흑) is block diagonal and has non-zero submatrices
of rank 1 each. In this case, we need at least two different doses, say 푥1 and 푥2, to obtain a combined non-singular information
matrix 푰(푥1,흑) + 푰(푥2,흑). The first cohort receives the lowest dose in our adaptive trial and the optimality criterion is applied
to the second cohort onwards. As a result, the singularity will not be an issue in implementing the method, as the second cohort
has the opportunity to receive any dose other than the lowest one to ensure non-singularity. Note that 푰(푥,흑) is used in (2) to
find the optimum dose in (3). At each stage of a trial, the prior distribution 푝(흑) is utilised with the responses so far to obtain
the posterior means 흑̂푘 of the parameters. These means are then used in a dose-optimisation criterion to obtain the dose for the
next cohort. That is to say, the prior that we assume is being used in both the parameter estimation stage and in the design stage,
though not in the same way as the standard Bayesian approach.
5.2 Simulation settings
Six dose-response scenarios are considered for the simulation study, as shown in Figure A1 . The parameter values for these
scenarios are chosen to obtain various shapes for the dose-response curves. For each scenario, it is assumed that 20 doses are
available in the set  = {0.5, 1.0,… , 10.0} and that the acceptable level for the probability of toxicity is 훾 = 0.2. Also, the
minimum success probability that an OD should have is assumed to be 훿 = 0.5. To check stopping for futility and/or toxicity, we
set 휆 = 훿− 훾 = 0.3. We take the dense grid of dose levels to examine the methodology. In practice, there may be fewer available
dose levels, but the procedure should not be affected by this. The true OD in Scenario 1 is 0.5, since it has a probability of success
greater than 0.5 and a probability of toxicity less than 0.2. Any dose of 1.5 or greater is toxic for this scenario, as the probability
of toxicity at these doses is above 훾 . Doses 5.5 and 6 are the true ODs in Scenario 2, where doses 6.5 and greater are toxic. The
true OD in Scenario 3 is 5.5-7.5, as the success curve is flat here. Doses beyond 8 are toxic in this scenario. Dose 10 is the true
OD in Scenario 4, which has many lower non-efficacious doses. None of the doses are toxic in this scenario. Scenario 5 has a
very flat success curve. Since the minimum success probability for a dose to be an OD is 0.5, this scenario does not have an OD.
Since all of the doses have a probability of toxicity above the target toxicity rate of 0.2 in Scenario 6, it does not have a true OD.
FIGURE A1 ABOUT HERE
Each trial assigns the lowest available dose of 0.5 mg/kg body weight to a cohort of patients. Given a dose assigned under
a scenario, the dose-response outcomes are simulated from a trinomial distribution using the corresponding true probabilities
of the outcomes. After the first cohort, the dose escalation is based on the criterion in (6) or in (7), using the updated posterior
means of the dose-response parameters at each stage. The posterior means are obtained through numerical integration using
the R package cubature.25The package carries out adaptive multidimensional integration over hypercubes. As mentioned in
Section 5.1, we use a joint uniform prior distribution for 흑. The parameter space Θ̃ is chosen for each scenario so that the true
values of the parameters lie in the middle of the corresponding intervals. For instance, since Scenario 1 has the true parameters
흑 = (1.44, 0.26,−1.70, 0.25)푇 , we consider Θ̃ = {흑 ∈ Θ ∶ 0 < 휗1 < 2.88, 0 < 휗2 < 0.52, − 3.40 < 휗3 < 0, 0 < 휗4 < 0.50}.
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The same approach is followed for the other scenarios. Each trial is stopped following the rules described in Section 3, where it
is assumed that 푟 = 6 and 푚 = 20. The number of patients in each cohort is 3, that is, 푐 = 3.
OPTIMUM VALUES FOR 퐶푆 AND 퐶푇
To motivate the values for the control parameters 퐶푆 and 퐶푇 in the penalty function (4), we conduct the following investigation.
In Scenario 1 in Figure A1 , the true optimal dose lies at the beginning of the dose range. Since the probability of success is low
and the probability of toxicity is high at the higher doses, the penalty resulting from non-zero values of 퐶푆 and 퐶푇 will restrict
the dose selection from the end of the dose region: see Figure A1 .
In Scenario 2, the success rate is low at the beginning and the toxicity rate is high at the higher doses. Therefore, penalising
doses from both ends will keep the dose selection in the middle, where the true optimal dose lies. The success curve in Scenario
3 is of a flat type. Even at the early doses, success is quite high, and toxicity at the higher doses is not as high as in the previous
two scenarios. As a result, the penalty for taking observations from both ends is smaller than that for the previous scenario.
However, it still keeps the dose selection in the middle of the dose region. The true optimal dose in Scenario 4 is at the end
of the dose region. The probabilities of success and toxicity remain very low for more than one half of the available doses.
Also, this scenario does not have any dose for which the probability of toxicity is very high. Penalising observations for a low
success rate and a high toxicity rate gives very high penalty values for most of the early doses and thereby will keep the dose
selection at the upper end of the dose region. The success probabilities at various doses are very low in Scenario 5, and, more
importantly, the curve is flat. The toxicity probability reaches the acceptable level towards the upper end of the dose region. As
a consequence, we also obtain a flat penalty curve. As seen from Figure A1 , the penalty function will force us to select doses
from the beginning of the range. Scenario 6 is a scenario where the probability of toxicity is well above the target toxicity rate
throughout the dose range. The probability of success mainly increases with dose and we are likely to select doses from the
middle of the dose range because of the penalty function. Considering all of these, we plan to use (4) that penalises doses which
have either a low probability of success or a high probability of toxicity, or both.
Having decided on the non-zero values for the control parameters, we assume that they are the same, that is, 퐶푆 = 퐶푇 = 퐶 .
Since a non-zero value of 퐶 will keep more patients away from doses with a low chance of efficacy or from highly toxic doses,
we need to use its optimum value. A strong penalty, that is, a larger value of 퐶 , will result in designs far from non-penalised
퐷-optimum designs. Although the details are not presented here, we have found that values of 퐶 larger than 1 considerably
compromised the precision of estimation. As the proposed dose-optimisation criterion is intended to improve the parameter
estimates, we have decided to use퐶 = 1. This value worked well in terms of preventing the frequent choice of undesirable doses.
5.3 Numerical results
With the control parameter values set to 1, we run the penalised combined criterion for each of the scenarios. One thousand
simulated trials are generated in each case for various values of the weight 푎. Note that, when 푎 = 0, the dose selection is
based on the probability of success only. On the other hand, the criterion reduces to the penalised 퐷-criterion for 푎 = 1: see
(6). Table A1 gives the simulation results for the penalised combined criterion for the scenarios considered. The higher the
values of %OD and %AD are, the better the design is. Similarly, %TD is expected to be as small as possible. The sampling and
decision efficiency measures can be obtained once the distributions of dose allocation and optimum dose selection are available,
as presented in Section 4. The information per observation and per cost and various risk measures are also obtained following
Section 4. We expect the information per observation and per cost to be as high as possible. Similarly, the risks are expected to
be as low as possible. Although many measures are presented, the best 푎 is based on the DE, as this reflects the quality of the
decision regarding the future of an experimental drug.
Consider the results for Scenario 1. The penalised퐷-criterion (푎 = 1) gives better results than maximisation of the probability
of success only (푎 = 0) in terms of most of the measures. However, the SE is the highest when 푎 = 0. This is expected, as
the criterion based on the maximisation of the probability of success is defined so that more patients are treated during the
trial with efficacious doses. The penalised 퐷-optimum criterion does not take care of this. The design performs the best overall
when 푎 = 0.8, indicating the importance of the penalised 퐷-criterion. Here, the design can identify the true optimum dose 0.5
most accurately. Only a few trials recommended toxic doses for further study in the next phase. About 48.5% of the cohorts are
treated at the OD throughout the trials. The decision efficiency is very high in this case (0.918), while the sampling efficiency is
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reasonable. For 6.4% of the time, no dose is recommended as the OD. Since this scenario has the very first dose as the true OD,
many trials are likely to stop for toxicity in the simulations. The average number of cohorts in a trial is very similar, apart from
the case when 푎 = 1.0. Both the information per observation and the information per cost increase as 푎 increases. The risk for the
targeted population is minimum when 푎 = 0.8. As 푎 increases, the risks for both the patient sample and the 푛th patient increase.
This is obvious as the design puts more weight on penalised 퐷-optimality with the increase in 푎. Note that 10,000 simulated
trials are generated for the benchmark design in each scenario. It is clear from the measures that our design outperforms the
nonparametric benchmark design described in Section 4. Some of the measures are absent for the benchmark design because of
its construction. Since here each patient is exposed to all of the dose levels, calculating %AD and SE will not make any sense.
For the same reason, we do not compute the risks for the patient sample and the 푛th patient. The average cohort size is 20, as
we use 60 patients in each simulated trial to be consistent with our design. The information per observation and per cost are not
calculated, as the benchmark design does not use the퐷-optimality criterion at all. The results obtained from the simulated trials
utilising the simple combined criterion in (7) are presented in Table A2 . Whereas the penalised combined criterion selects the
true OD 91.7% of the time when 푎 = 0.8, the simple combined criterion selects this dose only 88.4% of the time. On the whole,
the combined criterion with 푎 = 0.8 enhances the performance for Scenario 1, whether 퐷-optimality is penalised or not.
TABLES A1 AND A2 ABOUT HERE
Now consider the results for Scenario 2 in Table A1 . The best result in terms of the DE is attained when 푎 = 0.4. Of the
other values, 푎 = 0.0 and 푎 = 0.6 also provide satisfactory results. In fact, there is little variation in the performance for the
values of 푎 between 0 and 0.6. The most noticeable difference is observed for 푎 = 1. For this choice of weight, the design
identifies the ODmuch less accurately compared with the other weights. Fewer cohorts are treated with the optimum dose as the
weight increases and there is also a sharp drop when 푎 = 1. The efficiency measures DE and SE are both considerably smaller
in this case as well. The ratio of the probability of correct identification of the true OD at 푎 = 0.4 relative to the benchmark is
70.4 ÷ 71.5 × 100 = 98%. However, the DE at 푎 = 0.4 is well above that for the benchmark design. As seen in Table A2 , the
simple combined criterion produces very similar results for this scenario. However, the best 푎 is observed at 0.0.
We obtain similar results for the weights ranging between 0 and 0.8 in Scenario 3 in Table A1 . The best 푎 is observed at
0.4. As in the previous scenario, we observe a decreasing trend in the measures %AD for dose allocation and SE, with a sharp
drop at 푎 = 1. All of the performance values indicate that the penalised 퐷-criterion on its own is performing poorly compared
to the other cases. However, it might be worth combining the criteria in this case, with 푎 ∈ [0.2, 0.8]. Also, the proposed
design outperforms the benchmark design in this scenario. Similar conclusions can be drawn in the case of the simple combined
criterion, as seen in Table A2 .
For the penalised combined criterion in Scenario 4, it can be argued that the design is performing similarly for weights
between 0.4 and 0.8. But the penalised퐷-optimum design on its own is not performing well in this scenario either. The proposed
design is more efficient than the benchmark design in identifying the true OD. However, the DE for the benchmark design is
the maximum value in this scenario. This happens as the distribution of the estimated OD for the benchmark design is more
centred around the true OD than for the other design: see Scenario 4 in Figures 2, 3 and 5 in the Supplementary Material. A
good percentage of trials do not recommend any dose for further development in this scenario. As the highest dose is the true
OD here, a trial has more chance to stop early for futility. The results obtained for the simple combined criterion are found to
be quite competitive with those for the penalised combined criterion.
The design is most efficient when 푎 = 1 in Scenario 5. The DE decreases until 푎 = 1. The design is equally as efficient
as the benchmark design when 푎 = 1. Similar results are found when the simple combined criterion is used. In Scenario 6,
the performance of the penalised combined criterion is very similar across the values of 푎. In addition, the DE of our design
at these values is well above that of the benchmark design. The average number of cohorts utilised in each trial is very small.
Also, the results are very consistent with those produced by the simple combined criterion in Table A2 . Since a very small
number of cohorts is used in each trial, the penalised/simple combined criterion has little rôle in the identification of the OD. It
is the stopping rule for futility and/or toxicity that plays the significant rôle and leads to the very similar results. For the last two
scenarios, the DE has been computed as described in Section 4. Note that the DE in these scenarios is the same as %ND. We
cannot compute the SE here as 푥OD does not exist. For the same reason, we cannot find %AD for these scenarios. However, to
facilitate the computation of various risks, we assume that the true OD is 0.
It is worth mentioning that the SE and %AD are large when 푎 = 0 and small when 푎 = 1 for the first four scenarios considered,
whether the penalised 퐷-criterion is used or not. This is because maximisation of the probability of success allocates most of
the cohorts to the most efficacious doses compared to the 퐷-criterion. When we penalise the 퐷-criterion for low efficacious or
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highly toxic doses, the improvement in the SE is, however, noticeable. The combined criterion performs well with respect to
these measures. In Scenario 4, the SE values are close to each other, apart from the one corresponding to 푎 = 1. This is a scenario
where we do not have any dose for which the probability of toxicity exceeds the acceptable level, but it has many doses for which
the probability of success is very low. Therefore, the differences among the measures are not very substantial for this scenario.
Interesting observations can also be made by comparing the results for penalised and non-penalised 퐷-optimality, that is,
when 푎 = 1. Tables A1 and A2 clearly show the superiority of the penalised criterion. Most of the measures have better
values. Also, the penalised 퐷-optimum design (푎 = 1) always requires on average more cohorts than the designs for 푎 = 0 and
for the best 푎. The penalised combined criterion with the best 푎 needs very similar numbers of cohorts to the design with 푎 = 0.
A similar trend is found when the simple combined criterion is utilised.
The information per observation and per cost increase as 푎 increases across the scenarios. However, the trend in Scenario
6 is different, as the penalised combined criterion has little rôle here because of the small number of cohorts. The risk for the
targeted population is minimum at the best 푎. Both the risk for the patient sample and that for the 푛th patient increase with the
increase in 푎 for the scenarios. A similar trend is found with the simple combined criterion. As this criterion does not employ a
penalty function, the information per cost is not computed.
Figures 1 and 2 in the Supplementary Material show the distribution of the estimated OD obtained in the simulations at
various values of 푎 for the scenarios. For convenience, %ND is presented above 0. The penalised combined criterion ensures
that the most appropriate doses are recommended more often than too toxic and non-efficacious ones. Also, %ND is usually
smaller at the best 푎 in Scenarios 1-4 compared to the other values.
The distribution of the estimated OD for the nonparametric benchmark design is presented in Figure 3 in the Supplementary
Material. This design recommends many toxic doses as the OD in Scenario 1. The ODs recommended for Scenario 2 are
centred around the true OD. Many toxic doses are recommended as the OD in Scenario 3 and not many non-efficacious ones
are recommended in Scenario 4. Also, %ND is smaller compared to the penalised combined criterion for this scenario. The
benchmark produced in Scenario 5 is quite satisfactory, whereas many toxic doses are identified as the OD in Scenario 6.
The distribution of the estimated OD obtained for the simple combined criterion is presented in Figures 4 and 5 in the
Supplementary Material. Many trials recommend no dose as the OD in Scenario 1. The distribution is very similar to the
penalised combined criterion for Scenario 2. Many toxic doses are recommended as the OD when 푎 = 1 in Scenario 3. Like
the penalised combined criterion, many trials recommend no dose as the OD when 푎 = 1 in Scenario 4. The distributions in
Scenarios 5 and 6 are very similar to their penalised combined criterion counterparts.
6 DISCUSSION
We have looked at three different approaches for dose finding. In the first approach, the intention is to allocate doses to the
patients that are most efficacious according to the current knowledge while searching for the best dose, an approach known in
the literature as the “best intention". The second approach targets the most effective, from the parameter estimation point of
view, gathering of information and consequently should give the best estimate of the optimum dose. The third approach tries to
achieve a trade-off between the two. Best intention designs are ethically attractive, as they take care of the patients, but, unlike
the one based on the 퐷-optimality criterion, they have limitations in terms of convergence to the optimum dose. Pronzato13
and Fedorov et al14 report that “best intention" designs may converge to a sub-optimal dose. Their studies are based on the
frequentist approach and use the least squares or the maximum likelihood estimates of the parameters.
We are using Bayesian parameter estimation, and, to our knowledge, the convergence properties are not known in this case.
The best intention design may converge to a sub-optimal dose due to the possibility of poor estimates of the parameters. This
possibility is embedded in the criterion (1), which chooses the optimum dose for efficacy, rather than for precise estimation
of the parameters. It may happen that, when the responses are successes for the same dose given to a number of consecutive
cohorts, the algorithm will not have explored many other doses. For a small number of cohorts, we have observed that, on some
occasions, the algorithm chooses a sub-optimal dose. In the majority of cases, the algorithm stops at the true optimum dose, as
shown in Tables A1 and A2 . However, as seen, combining the two approaches on the whole can improve the performance of
the adaptive design.
Maximum likelihood estimates of the parameters are often used in finding퐷-optimum designs. But, to form a valid estimator,
one needs sufficient information. That is to say, a likelihood equation has no solution until all types of outcomes are observed.
On many occasions, we have found toxic outcomes not to be observed, even after applying doses to 10 of the cohorts. Therefore,
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we use Bayesian parameter estimates. Note that, to be consistently Bayesian, a total information matrix should be used in (2)
by adding to푴 the information matrix for the uniform prior distribution defined in Section 5.1. However, this possibility is not
considered here.26
The gains in the combined criteria over the penalised퐷-criterion or퐷-criterion are evident from the presented results. All of
the performance measures are found to be improved. Most importantly, we notice an appreciable improvement in the quality of
treatment allocation, reflected through the sampling efficiency measure SE and the measure of OD allocation during the trial,
%AD. The quality of optimum dose selection for the next phase, presented through the DE, is also found to be improved. The
combined criteria also outperform the criterion based on the maximisation of the probability of success. In general, the combined
criteria utilise a reasonable number of cohorts compared to the other two designs.
All of these results guide us to recommend the proposed combined criteria as dose-optimisation tools in early phase clinical
trials. In terms of performance, the penalised combined criterion does slightly better than the simple combined criterion. The
choice of values for 푎will solely depend on the objective. In extreme scenarios like 1, 4, 5 and 6, we have seen that high values of
푎 perform surprisingly well. The middle values are also found to perform satisfactorily in the majority of the scenarios. Since, in
reality, we may not know the shape of the dose-response relationship in advance of the trial, we suggest using the middle values.
Alternatively, we can have some idea of the optimum value of 푎 during the progress of a trial. After a reasonable number of
stages, we can locate where the optimum dose may lie based on the current estimates of the probabilities of success and toxicity.
If it is found to be either at the lower end or at the upper end of the dose region, we can use higher values of 푎 afterwards.
However, if the OD is likely to be in the middle of the dose region, we can use middle values of 푎.
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FIGURE A1 Dose-response scenarios for the continuation ratio model. The respective parameter values are: Scenario 1, 흑 =
(1.44, 0.26,−1.70, 0.25)푇 ; Scenario 2, 흑 = (−3.50, 1.00,−6.00, 0.72)푇 ; Scenario 3, 흑 = (−0.80, 0.50,−3.80, 0.30)푇 ; Scenario
4, 흑 = (−6.50, 0.75,−8.00, 0.65)푇 ; Scenario 5, 흑 = (−1.05, 0.05,−2.47, 0.15)푇 ; and Scenario 6, 흑 = (−0.6, 0.3,−1.1, 0.09)푇 .
The horizontal dashed line indicates the acceptable level for toxicity and the penalty functions for the scenarios are obtained
assuming that 퐶푆 = 퐶푇 = 1.
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TABLE A1 Performance of the penalised combined criterion for the six scenarios. Percentage of optimum doses chosen as the
true optimum one, recommended for further studies (%OD), percentage of no dose recommended (%ND), percentage of doses
recommended as optimum, but carrying the probability of toxicity above the acceptable level (%TD), percentage of cohorts
treated at the true optimum doses throughout the trials (%AD), decision efficiency (DE), sampling efficiency (SE) and some
other measures. The value of 푎 in bold is regarded as the best in terms of the performance measure DE. Note that 푏(휋̂) is the
nonparametric benchmark.
Risk
Scenario 푎 %OD %ND %TD %AD DE SE Averagecohorts
Info. per
obs.
Info. per
cost
Targeted
population
Patient
sample
푛th
patient
0.0 63.2 5.6 21.6 42.9 0.728 0.593 10.5 0.003 0.083 0.563 14.7 1.42
0.2 72.6 6.5 17.8 48.2 0.757 0.547 10.3 0.009 0.125 0.455 17.9 1.73
1 0.4 75.6 7.7 15.2 45.8 0.771 0.481 11.2 0.046 0.212 0.469 39.7 3.54
0.6 86.8 6.2 6.6 50.2 0.872 0.508 11.0 0.087 0.247 0.255 51.4 4.66
0.8 91.7 6.4 1.7 48.5 0.918 0.484 11.7 0.136 0.266 0.084 72.0 6.13
1.0 76.1 14.1 6.3 34.0 0.796 0.339 15.6 0.188 0.272 0.133 151.5 9.47
푏(휋̂) 28.0 14.9 37.9 - 0.472 - 20.0 - - 1.495 - -
0.0 68.8 3.8 7.7 39.4 0.872 0.665 16.8 0.011 0.093 1.423 62.9 3.74
0.2 66.3 4.1 8.0 38.9 0.863 0.656 16.9 0.012 0.094 1.533 63.8 3.78
2 0.4 70.4 2.6 7.0 39.2 0.890 0.656 17.3 0.013 0.098 1.050 64.7 3.74
0.6 68.4 3.4 7.5 37.0 0.876 0.625 17.7 0.019 0.107 1.308 68.4 3.86
0.8 67.4 4.9 8.8 34.7 0.847 0.603 18.3 0.025 0.114 1.795 74.1 4.05
1.0 41.0 7.7 5.1 17.2 0.777 0.498 19.7 0.043 0.118 3.508 104.9 5.31
푏(휋̂) 71.5 0.0 5.2 - 0.863 - 20.0 - - 0.288 - -
0.0 88.7 0.2 1.5 58.7 0.974 0.869 18.0 0.095 0.332 0.765 103.8 5.78
0.2 87.1 0.2 2.1 57.7 0.967 0.851 18.1 0.104 0.339 0.816 105.9 5.84
3 0.4 89.4 0.1 1.2 57.7 0.978 0.839 18.2 0.116 0.348 0.742 107.5 5.89
0.6 88.3 0.2 2.2 54.7 0.967 0.802 18.6 0.141 0.364 0.868 113.7 6.11
0.8 87.2 0.1 2.2 51.0 0.968 0.766 18.9 0.176 0.382 0.874 121.7 6.44
1.0 60.9 0.0 1.6 26.5 0.921 0.657 20.0 0.334 0.442 3.797 205.8 10.30
푏(휋̂) 76.3 0.0 5.2 - 0.935 - 20.0 - - 1.113 - -
0.0 71.2 15.1 0.0 28.6 0.816 0.544 17.9 0.017 0.007 16.025 355.1 19.78
0.2 71.7 13.6 0.0 28.7 0.821 0.542 17.9 0.017 0.007 14.996 357.0 19.88
4 0.4 74.4 13.6 0.0 29.7 0.829 0.541 17.8 0.017 0.007 14.404 356.5 20.06
0.6 73.1 14.3 0.0 29.4 0.814 0.538 17.8 0.017 0.007 15.335 358.0 20.10
0.8 76.6 11.8 0.0 31.0 0.847 0.539 17.6 0.017 0.007 12.788 356.0 20.21
1.0 47.9 23.7 0.0 26.4 0.647 0.506 19.2 0.018 0.007 26.495 381.7 19.84
푏(휋̂) 60.1 10.4 0.0 - 0.873 - 20.0 - - 10.480 - -
0.0 - 84.4 10.2 - 0.844 - 17.3 1.699 0.215 10.785 615.4 35.54
0.2 - 79.4 16.9 - 0.794 - 16.6 2.069 0.228 17.115 628.5 37.82
5 0.4 - 73.8 22.7 - 0.738 - 16.4 2.499 0.245 22.898 661.8 40.3
0.6 - 66.0 28.8 - 0.660 - 16.2 2.992 0.262 28.865 660.5 40.72
0.8 - 57.3 32.7 - 0.573 - 15.6 3.833 0.281 32.746 617.3 39.41
1.0 - 99.9 0.0 - 0.999 - 17.5 2.858 0.270 0.000 569.2 32.49
푏(휋̂) - 99.9 0.0 - 0.999 - 20.0 - - 0.015 - -
0.0 - 99.1 0.9 - 0.991 - 1.9 0.097 0.037 0.337 21.4 11.23
0.2 - 99.8 0.2 - 0.998 - 1.7 0.081 0.036 0.200 13.3 7.57
6 0.4 - 99.8 0.2 - 0.998 - 1.8 0.084 0.037 0.048 15.3 8.47
0.6 - 99.7 0.3 - 0.997 - 1.9 0.115 0.044 0.242 19.3 9.89
0.8 - 99.5 0.5 - 0.995 - 1.8 0.102 0.037 0.500 17.5 9.70
1.0 - 99.9 0.1 - 0.999 - 1.9 0.137 0.038 0.016 17.7 9.28
푏(휋̂) - 93.5 6.5 - 0.935 - 20.0 - - 2.054 - -
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TABLE A2 Performance of the simple combined criterion for the six scenarios. Percentage of optimum doses chosen as the
true optimum one, recommended for further studies (%OD), percentage of no dose recommended (%ND), percentage of doses
recommended as optimum, but carrying the probability of toxicity above the acceptable level (%TD), percentage of cohorts
treated at the true optimum doses throughout the trials (%AD), decision efficiency (DE), sampling efficiency (SE) and some
other measures. The value of 푎 in bold is regarded as the best in terms of the performance measure DE. Note that 푏(휋̂) is the
nonparametric benchmark.
Risk
Scenario 푎 %OD %ND %TD %AD DE SE Averagecohorts
Info. per
obs.
Info. per
cost
Targeted
population
Patient
sample
푛th
patient
0.0 64.3 6.2 20.0 44.6 0.738 0.606 10.3 0.003 - 0.464 13.4 1.31
0.2 68.8 5.5 19.6 45.2 0.749 0.589 10.6 0.005 - 0.475 17.1 1.61
1 0.4 73.0 7.7 16.1 43.6 0.762 0.469 11.6 0.043 - 0.454 41.6 3.57
0.6 80.5 9.8 8.8 46.6 0.814 0.473 11.4 0.117 - 0.286 65.7 5.74
0.8 88.4 7.3 3.7 46.0 0.889 0.460 12.1 0.214 - 0.143 104.4 8.62
1.0 40.0 32.4 15.0 16.8 0.526 0.168 18.8 0.272 - 0.333 354.6 18.87
푏(휋̂) 28.0 14.9 37.9 - 0.472 - 20.0 - - 1.495 - -
0.0 68.5 2.2 7.7 40.0 0.887 0.669 16.8 0.010 - 0.930 62.6 3.73
0.2 69.6 3.8 7.9 39.9 0.871 0.658 17.0 0.011 - 1.405 63.5 3.73
2 0.4 69.2 3.7 7.5 39.6 0.876 0.652 17.2 0.013 - 1.352 64.8 3.77
0.6 68.2 4.5 7.3 36.6 0.867 0.622 17.7 0.019 - 1.665 69.1 3.90
0.8 66.5 4.4 6.3 34.7 0.877 0.604 18.3 0.026 - 1.620 74.5 4.07
1.0 42.7 7.4 6.8 13.1 0.747 0.387 19.8 0.058 - 3.782 141.4 7.14
푏(휋̂) 71.5 0.0 5.2 - 0.863 - 20.0 - - 0.288 - -
0.0 86.3 0.0 2.3 57.9 0.967 0.866 17.8 0.094 - 0.776 104.3 5.8
0.2 89.5 0.1 1.6 58.3 0.974 0.858 18.1 0.100 - 0.719 104.8 5.8
3 0.4 88.9 0.1 1.3 56.8 0.977 0.836 18.2 0.117 - 0.723 108.2 5.9
0.6 88.2 0.2 2.2 54.7 0.967 0.800 18.6 0.145 - 0.810 113.7 6.1
0.8 88.2 0.1 2.2 50.6 0.968 0.758 18.9 0.182 - 0.883 123.0 6.5
1.0 77.8 0.2 5.0 29.2 0.914 0.657 19.9 0.365 - 2.466 226.3 11.3
푏(휋̂) 76.3 0.0 5.2 - 0.935 - 20.0 - - 1.113 - -
0.0 69.0 15.7 0.0 27.9 0.795 0.542 18.0 0.016 - 17.268 356.7 19.8
0.2 71.6 13.2 0.0 28.4 0.818 0.542 17.9 0.017 - 14.680 355.0 19.8
4 0.4 68.6 15.6 0.0 28.4 0.794 0.536 17.9 0.016 - 17.059 361.7 20.2
0.6 75.5 12.1 0.0 30.2 0.836 0.540 17.7 0.017 - 13.552 356.5 20.2
0.8 76.1 10.6 0.0 31.0 0.847 0.539 17.6 0.017 - 11.879 354.0 20.1
1.0 32.2 30.0 0.0 24.8 0.523 0.491 19.7 0.018 - 34.431 404.0 20.5
푏(휋̂) 60.1 10.4 0.0 - 0.873 - 20.0 - - 10.480 - -
0.0 - 81.3 12.4 - 0.813 - 17.3 1.733 - 13.300 618.8 35.7
0.2 - 78.8 16.5 - 0.788 - 16.8 2.038 - 16.691 642.5 38.2
5 0.4 - 76.7 20.7 - 0.767 - 16.7 2.392 - 20.820 659.2 39.5
0.6 - 62.9 32.3 - 0.629 - 16.1 3.170 - 32.371 671.5 41.7
0.8 - 53.3 39.3 - 0.533 - 15.7 4.175 - 39.342 660.1 42.0
1.0 - 100.0 0.0 - 1.000 - 17.5 3.008 - 0.000 591.1 33.8
푏(휋̂) - 99.9 0.0 - 0.999 - 20.0 - - 0.015 - -
0.0 - 99.5 0.5 - 0.995 - 1.8 0.087 - 0.251 14.8 8.2
0.2 - 99.8 0.2 - 0.998 - 1.8 0.090 - 0.142 13.9 7.7
6 0.4 - 99.7 0.3 - 0.997 - 1.8 0.100 - 0.137 19.1 10.5
0.6 - 99.4 0.6 - 0.994 - 1.8 0.105 - 0.317 17.3 9.4
0.8 - 99.7 0.3 - 0.997 - 1.8 0.093 - 0.212 18.9 10.3
1.0 - 99.7 0.3 - 0.997 - 1.8 0.103 - 0.115 13.0 7.3
푏(휋̂) - 93.5 6.5 - 0.935 - 20.0 - - 2.054 - -
